# An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)

> **NCT07220603** · PHASE2 · RECRUITING · sponsor: **PepGen Inc** · enrollment: 48 (estimated)

## Conditions studied

- Myotonic Dystrophy 1

## Interventions

- **DRUG:** PGN-EDODM1

## Key facts

- **NCT ID:** NCT07220603
- **Lead sponsor:** PepGen Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-23
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07220603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07220603, "An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT07220603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*